{"id":"d1fd6d55-bf1a-45e2-9612-d40019d2d867","companyId":"392e4009-60dd-429d-b989-033a7d4de53d","modelName":"Maestro","slug":"moon-maestro","description":"Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.","formFactor":"surgical","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Moon Surgical (private; Paris + San Carlos CA; CEO Anne Osdoit; board chair Fred Moll, Intuitive co-founder; backers Sofinnova + NVentures/NVIDIA) makes Maestro, a laparoscopic surgical-ASSISTANT/collaboration robot (holds/positions instruments alongside the surgeon, not a full teleop console). Commercial Maestro FDA 510(k)-cleared Jun 5 2024 (K240598); >1,100 patients treated across US + Europe (company-stated). ~$90M+ raised."},{"label":"AI-substance: genuine SHIPPED AI (notable)","value":"ScoPilot is a genuine SHIPPED, FDA-cleared AI feature (intraoperative scope control via NVIDIA Holoscan), with a PCCP - not merely demonstrated. This distinguishes Maestro from the teleop-only platforms in this cohort. Maestro itself is a collaborative/assist robot (an honest distinction from full master-slave teleop)."},{"label":"CORRECTION (pathway)","value":"Maestro went the 510(k) route (K240598), NOT de novo (the dispatch hypothesized de novo). De novo around that time was Virtual Incision/MIRA and MMI/Symani - different companies."},{"label":"Claimed but NOT verified","value":"CE mark status/date (unverified this pass); exact installed-system count; the 'industry's first AI on a commercial surgical robot' superlative (marketing); the >1,100-patients figure (company-sourced)."}],"products":"Maestro: a laparoscopic surgical-assistant platform (holds/positions instruments + endoscope alongside the surgeon). ScoPilot: shipped AI software (NVIDIA Holoscan-powered) for intraoperative scope control. Commercial Maestro FDA 510(k) K240598 cleared Jun 5 2024; ScoPilot FDA-cleared 2025 with a Predetermined Change Control Plan (PCCP).","formFactor":"surgical (laparoscopic surgical-assistant / collaboration robot: holds + positions instruments alongside the surgeon; not full master-slave teleop)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.prnewswire.com/news-releases/moon-surgical-second-fda-clearance-commercial-maestro","title":"Moon Surgical: 2nd FDA clearance covering the commercial Maestro system (Jun 2024)","sourceName":"Moon Surgical (PR Newswire)"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K240598","title":"FDA 510(k) K240598: Maestro System (cleared Jun 5 2024)","sourceName":"FDA (accessdata)"},{"url":"https://www.biospace.com/moon-surgical-scopilot-fda-nvidia-holoscan","title":"Moon Surgical ScoPilot AI FDA clearance (with PCCP; NVIDIA Holoscan)","sourceName":"BioSpace"},{"url":"https://www.massdevice.com/moon-surgical-funding-fred-moll/","title":"Moon Surgical raises $55.4M; Fred Moll board chair; NVentures-backed","sourceName":"MassDevice"}],"aliases":["Maestro","Moon Maestro","ScoPilot"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:13:22.252Z","updatedAt":"2026-06-03T20:13:22.252Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/moon-maestro","url":"https://registry.deploy.report/models/moon-maestro","name":"Maestro","alternateName":["Maestro","Moon Maestro","ScoPilot"],"description":"Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.","identifier":"d1fd6d55-bf1a-45e2-9612-d40019d2d867","category":"surgical","publisher":{"@id":"https://deploy.report/#organization"}}}